Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.45−0.00 (-0.65%)
Close on Nov 17, 2026Market cap $257.81KP/E –Yield –
Virax Biolabs price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Virax Biolabs's price to sales ratio was 29.2× on Nov 11, 2026, against 276.1× a year earlier. Over the last 3 years it ranged from 16.1× to 445.5×, with a median of 130.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 29.2× | −207.9 |
| 2025 | Dec 31, 2025 | 237.2× | +200.1 |
| 2024 | Dec 31, 2024 | 37.0× | −228.1 |
| 2023 | Dec 29, 2023 | 265.1× | – |
See a number that looks wrong?